<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04723953</url>
  </required_header>
  <id_info>
    <org_study_id>PET/MR-Cardiology</org_study_id>
    <nct_id>NCT04723953</nct_id>
  </id_info>
  <brief_title>Cardiac Fibroblast Activation Detected by 68Ga-FAPI PET/MR</brief_title>
  <official_title>Cardiac Fibroblast Activation Detected by 68Ga-FAPI PET/MR is a Prognostic Indicator in Patients With Myocardial Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myocardial infarction is the most common cause of high mortality in the modern world. The&#xD;
      short-term survival rate of ST-elevated myocardial infarction (STEMI) has been dramatically&#xD;
      increased in the past decades thanks to primary coronary intervention and standardization of&#xD;
      treatment. However, the long-term prognosis of patients with acute myocardial infarction&#xD;
      (AMI) is still poor, especially in the aging population, due to heart failure related to&#xD;
      inappropriate myocardial fibrosis and subsequent left ventricular (LV) remodeling. Despite&#xD;
      the amelioration of STEMI management, LV remodeling still occurs in approximately 1/3 of all&#xD;
      STEMI patients. Therefore, early identification of such patients may help the optimization of&#xD;
      therapy and eventually the outcomes.&#xD;
&#xD;
      One characteristic of activated cardiac fibroblasts is the expression of FAP (fibroblast&#xD;
      activation protein). A tracer (FAP inhibitor) for positron emission tomography that targets&#xD;
      FAP has been used to measure relative FAP density indicative of activated fibroblasts in&#xD;
      different cancer entities. However, whether it can reliably assess myocardial fibrosis and&#xD;
      predict the poor prognosis caused by LV remodeling is not yet known. Therefore, We aim to&#xD;
      observe active myocardial fibrosis process in patients with AMI, and analyze its relationship&#xD;
      with the patients'prognosis in a longitudinal study through 68Ga-FAPI PET/MRI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target-to-background Ratio (TBR)</measure>
    <time_frame>One week after acute myocardial infarction</time_frame>
    <description>68Ga-FAPI uptake ratio of highly active fibrotic myocardium to heart blood pool on PET images</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic volume (MV)</measure>
    <time_frame>One week after acute myocardial infarction</time_frame>
    <description>Volume of highly active fibrotic myocardium on PET images</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infarction size (IS)</measure>
    <time_frame>One week after acute myocardial infarction</time_frame>
    <description>Percentage of late gadolinum enhancement area in the entire myocardium on MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ejection fraction (EF)</measure>
    <time_frame>One week after acute myocardial infarction</time_frame>
    <description>Left ventricular ejection function evaluated on MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target-to-background Ratio (TBR)</measure>
    <time_frame>Six months after acute myocardial infarction</time_frame>
    <description>68Ga-FAPI uptake ratio of highly active fibrotic myocardium to heart blood pool on PET images</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic volume (MV)</measure>
    <time_frame>Six months after acute myocardial infarction</time_frame>
    <description>Volume of highly active fibrotic myocardium on PET images</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infarction size (IS)</measure>
    <time_frame>Six months after acute myocardial infarction</time_frame>
    <description>Percentage of late gadolinum enhancement area in the entire myocardium on MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ejection fraction (EF)</measure>
    <time_frame>Six months after acute myocardial infarction</time_frame>
    <description>Left ventricular ejection function evaluated on MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NT-pro-BNP</measure>
    <time_frame>One week after acute myocardial infarction</time_frame>
    <description>Serum marker of chronic heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP</measure>
    <time_frame>One week after acute myocardial infarction</time_frame>
    <description>Serum marker of acute myocardial inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-pro-BNP</measure>
    <time_frame>Six months after acute myocardial infarction</time_frame>
    <description>Serum marker of chronic heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP</measure>
    <time_frame>Six months after acute myocardial infarction</time_frame>
    <description>Serum marker of acute myocardial inflammation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Myocardial Remodeling After AMI</condition>
  <arm_group>
    <arm_group_label>Acute myocardial infarction patient group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>68Ga-FAPI PET/MRI</intervention_name>
    <description>PET and MRI in patients with acute myocardiac infarction are simultaneously analyzed using hybrid PET/MRI device for monitoring myocardial fibrosis and function.</description>
    <arm_group_label>Acute myocardial infarction patient group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  between 18-75 years old&#xD;
&#xD;
          -  diagnosed with coronary angiography&#xD;
&#xD;
          -  performed percutaneous coronary interventionï¼Œwith successful myocardial reperfusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unstable hemodynamics&#xD;
&#xD;
          -  MR contraindications (such as pacemaker or nerve stimulator or metal foreign body,&#xD;
             high fever, severe renal failure, etc.)&#xD;
&#xD;
          -  Claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Min Zhang, Dr.</last_name>
    <phone>0086-21-64370045</phone>
    <email>zm11518@rjh.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianqi Zhu, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

